De novo peptide design exhibits great potential in materials engineering, particularly for the use of plastic-binding peptides to help remediate microplastic pollution. There are no known peptide binders for many plastics-a gap that can be filled with de novo design. Current computational methods for peptide design exhibit limitations in sampling and scaling that could be addressed with quantum computing. Hybrid quantum-classical methods can leverage complementary strengths of near-term quantum algorithms and classical techniques for complex tasks like peptide design. This work introduces a hybrid quantum-classical generative framework for designing plastic-binding peptides combining variational quantum circuits with a variational autoencoder network. We demonstrate the framework's effectiveness in generating peptide candidates, evaluate its efficiency for property-oriented design, and validate the candidates with molecular dynamics simulations. This quantum computing-based approach could accelerate the development of biomolecular tools for environmental and biomedical applications while advancing the study of biomolecular systems through quantum technologies.
De novo peptide design exhibits great potential in materials engineering, particularly for the use of plastic-binding peptides to help remediate microplastic pollution. There are no known peptide binders for many plastics-a gap that can be filled with de novo design. Current computational methods for peptide design exhibit limitations in sampling and scaling that could be addressed with quantum computing. Hybrid quantum-classical methods can leverage complementary strengths of near-term quantum algorithms and classical techniques for complex tasks like peptide design. This work introduces a hybrid quantum-classical generative framework for designing plastic-binding peptides combining variational quantum circuits with a variational autoencoder network. We demonstrate the framework's effectiveness in generating peptide candidates, evaluate its efficiency for property-oriented design, and validate the candidates with molecular dynamics simulations. This quantum computing-based approach could accelerate the development of biomolecular tools for environmental and biomedical applications while advancing the study of biomolecular systems through quantum technologies.
We introduce a variational quantum autoencoder tailored for de novo molecular design named QOBRA (Quantum Operator-Based Real-Amplitude autoencoder). QOBRA le circuits for real-amplitude encoding and the SWAP test to estimate reconstruction and latent-space regularization errors during back-propagation. Adjoint encoderand decoder unitary transformations and a generative process that ensures accurate reconstruction as well as novelty, uniqueness, and validity of the generated samples. We showcase QOBRA as applied to de novo design of Ca 2+ -, Mg 2+ -, and Zn 2+ -binding metalloproteins after training the generative model with a modest dataset. Significance Statement Recent advancements in classical generative machine learning have shown significant strides in molecular design for targeted applications. N onetheless, these advancements are fundamentally limited by classical computation based on binary units. We introduce a quantum computation-based ML framework employing qubits, which exhibits the ability to synthesize de novo molecular instances with specified properties from limited datasets. Quantum networks require exponentially fewer parameters than classical ones, enhancing their trainability and efficiency. While our demonstration focuses on metalloprotein primary sequences, the paradigm is adaptable to diverse molecular designs. This integration of AI and quantum computing holds potential to expand the scientific and technological frontiers of both domains within a practical framework.
The de novo design of drug molecules is recognized as a time-consuming and costly process, and computational approaches have been applied in each stage of the drug discovery pipeline. Variational autoencoder is one of the computer-aided design methods which explores the chemical space based on an existing molecular dataset. Quantum machine learning has emerged as an atypical learning method that may speed up some classical learning tasks because of its strong expressive power. However, near-term quantum computers suffer from limited num-ber of qubits which hinders the representation learning in high dimensional spaces. We present a scalable quantum generative autoencoder (SQ-VAE) for simultaneously reconstructing and sampling drug molecules, and a corresponding vanilla variant (SQ-AE) for better reconstruction. The architectural strategies in hybrid quantum classical networks such as, adjustable quantum layer depth, heterogeneous learning rates, and patched quantum circuits are proposed to learn high dimensional dataset such as, ligand-targeted drugs. Extensive experimental results are reported for different dimensions including 8x8 and 32x32 after choosing suitable architectural strategies. The performance of quantum generative autoencoder is compared with the corre-sponding classical counterpart throughout all experiments. The results show that quantum computing advantages can be achieved for normalized low-dimension molecules, and that high-dimension molecules generated from quantum generative autoencoders have better drug properties within the same learning period.
The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
Variational Quantum Circuits (VQCs) have emerged as a cornerstone of hybrid quantum–classical algorithms designed to harness the computational potential of near-term quantum devices. By combining parameterized quantum gates with classical optimization, VQCs provide a flexible framework for tackling machine learning, chemistry, and optimization problems intractable for classical methods. This review comprehensively overviews VQC design principles, ansatz structures, optimization strategies, and real-world applications. Furthermore, we discuss fundamental challenges such as barren plateaus, the expressibility–trainability trade-off, and current noisy intermediate-scale quantum (NISQ) hardware limitations. Finally, we highlight emerging directions that could enable scalable, noise-resilient, and physically interpretable variational quantum models for future quantum computing applications
De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.